60 Assessing hyaluronidase-facilitated subcutaneous immunoglobulin 20% (fSCIG 20%) pharmacokinetics, safety and tolerability in primary immunodeficiency diseases: phase 2/3 study design
Richard LWasserman(ENT and Allergy), Zhaoyang Li(Guiyang Medical University), Colin Anderson‐Smits(Takeda (United States)), Alexander Bauer(Takeda (Austria)), Helen L. Leavis(University Medical Center Utrecht), Liang-Hui Chu(Takeda (United States)), Paz Carrasco(Baxalta (United States)), András Nagy(University of Szeged), Barbara McCoy(Baxalta (United States)), Immanuel Freedman(Takeda (United States))
Cited by 0
Related Papers
A Comprehensive Overview on Chemotherapy-Induced Cardiotoxicity: Insights into the Underlying Inflammatory and Oxidative Mechanisms
|Cardiovascular Drugs and Therapy|2024|38
Selected Abstracts from the 12th Annual Meeting of the Clinical Immunology Society: 2021 Virtual Annual Meeting: Immune Deficiency and Dysregulation North American Conference
|Journal of Clinical Immunology|2021|28
Long-term safety of hyaluronidase-facilitated subcutaneous immunoglobulin 10%: a European post-authorization study
|Immunotherapy|2024|5
Vitamin D and breast cancer
|Orvosi Hetilap|2014|4